Quick Answer
Travere Therapeutics, Inc. reported Operating Income Loss of -$62.82 million for the year ending 2025.
- Travere Therapeutics, Inc. showed an increase of +80.6% in Operating Income Loss from 2024 to 2025.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Travere Therapeutics, Inc.'s Operating Income Loss has declined by 107.6%.
- Historical annual values: Fiscal year 2025: -$62.82 million | Fiscal year 2024: -$323.83 million | Fiscal year 2023: -$388.14 million | Fiscal year 2022: -$319.81 million | Fiscal year 2021: -$199.43 million | Fiscal year 2020: -$176.16 million | Fiscal year 2019: -$137.36 million | Fiscal year 2018: -$80.04 million | Fiscal year 2017: -$53.79 million | Fiscal year 2016: -$58.21 million | Fiscal year 2015: -$50.75 million | Fiscal year 2014: -$79.81 million | Fiscal year 2013: -$24.77 million | Fiscal year 2012: -$30.26 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: